Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Age is nothing but a number

Nature Reviews Urology volume 10, pages 683–684 (2013)Cite this article

Subjects

Post-hoc analysis of phase III data of abiraterone in men with castration-resistant prostate cancer showed that survival did not differ according to patient age (≤75 years versus >75 years). Similar analyses of other agents have reported mixed findings. Should patient age be part of decision making?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Centers for Disease Control and Prevention. Life expectancy at birth, at age 65, and at age 75, by sex, race, and Hispanic origin: United States, selected years 1900–2010 [online], (2013).

  2. Mulders, P. F. et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2013.09.005.

  3. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

    Article  CAS  Google Scholar 

  4. Fizazi, K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983–992 (2012).

    Article  CAS  Google Scholar 

  5. Sternberg, C. et al. Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial [abstract 16]. J. Clin. Oncol. 31 (Suppl. 6), a16 (2013).

    Article  Google Scholar 

  6. de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).

    Article  CAS  Google Scholar 

  7. Parker, C. et al. α-Emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).

    Article  CAS  Google Scholar 

  8. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).

    Article  CAS  Google Scholar 

  9. Hamaker, M. E. et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 13, e437–e444 (2012).

    Article  Google Scholar 

Download references

Acknowledgements

The author acknowledges the support of the Sumner M. Redstone Charitable Foundation and the Skirball Foundation.

Author information

Authors and Affiliations

  1. Center for Applied Molecular Medicine, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CSC 240, Los Angeles, 90033, CA, USA

    Mitchell E. Gross

Authors
  1. Mitchell E. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitchell E. Gross.

Ethics declarations

Competing interests

The author has served on an advisory board and received research support from Janssen Research and Development.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gross, M. Age is nothing but a number. Nat Rev Urol 10, 683–684 (2013). https://doi.org/10.1038/nrurol.2013.265

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2013.265

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing